Malaria Information and Prophylaxis, by Country [E]

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Malaria Information and Prophylaxis by Country
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Easter Island (Chile) None Not Applicable Not Applicable Not Applicable
Ecuador; Including the Galápagos Islands Areas at altitudes <1,500 m (4,921 ft) in the provinces of Carchi, Esmeraldas, Morona Santiago, Orellana, and Pastaza. Rare cases in other provinces in areas <1,500m (4,921 ft). Not present in the cities of Guayaquil and Quito or the Galápagos Islands Chloroquine P. vivax 72%,

P. falciparum 28%

Areas with malaria in Carchi, Esmeraldas, Morona Santiago, Orellana, and Pastaza Provinces: Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6. Other areas with rare cases of malaria: Mosquito avoidance only.
Egypt None Not applicable Not applicable Not applicable
El Salvador Rare cases along the Guatemalan border None P. vivax 99%,

P. falciparum <1%

Mosquito avoidance only
Equatorial Guinea All Chloroquine P. falciparum 85%,

P. malariae,

P. ovale,

and P. vivax 15% combined

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Eritrea All areas at altitudes < 2,200 m (7,218 ft). None in Asmara. Chloroquine P. falciparum 85%,

P. vivax 10-15%,

P. ovale rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Estonia None Not Applicable Not Applicable Not Applicable
Ethiopia All areas < 2,500 m (8,202 ft), except none in the city of Addis Ababa. Chloroquine P. falciparum 60-70%,

P. vivax 30-40%,

P. malariae,

P. ovale rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2. Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. This risk estimate is based largely on cases occurring in US military personnel who travel for extended periods of time with unique itineraries that likely do not reflect the risk for the average US traveler.
6. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients must be screened for G6PD deficiency prior to starting primaquine.

Page last reviewed: March 27, 2019